- ISRAEL21c - http://www.israel21c.org -

Israeli biotech Macrocure sets terms for $75 million IPO

Posted By Viva Sarah Press On July 28, 2014 @ 5:08 am In | No Comments

Macrocure, a late-stage Israeli biotech developing white blood cell injections to treat hard-to-heal and chronic wounds, has announced terms for its $75 million IPO. The Petach Tikva company is offering 5.4 million shares, according to Renaissance Capital Investments.

Macrocure’s main product is CureXcell, a cell based therapy that when applied to a wound, restores the natural balance required for the wound healing process.

CureXcell has been approved as a medical device in Israel and has been used in more than 5,000 patients in commercial or clinical study settings with consistent results, according to Macrocure data.

Related Articles

Article printed from ISRAEL21c: http://www.israel21c.org

URL to article: http://www.israel21c.org/news/israeli-biotech-macrocure-sets-terms-for-75-million-ipo/

Copyright © 2012 Israel. All rights reserved.